EICHOR
● Completed
Safety and Immunogenicity of Different Formulations of an MF59-Adjuvanted Influenza Vaccine in Older Adults ≥50 Years of Age
Condition: Influenza, Human · Sponsor: Seqirus
About this study
This Phase 2, randomized, observer-blind, dose-confirmation clinical study evaluated different formulations of MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine. Approximately 1000 subjects were randomized into 1 of 4 possible treatment groups with approximately 250 participants per group. Every participant received an influenza vaccine injection on Day 1 and were to be followed up for approximately 6 months following injection. The primary immunogenicity analysis is based on Day 29 serology data.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (47)
| AMR Tempe | Tempe, Arizona, United States | — |
| Marvel Clinical Research | Huntington Beach, California, United States | — |
| California Research Center | San Diego, California, United States | — |
| The Lynn Institute of The Rockies | Colorado Springs, Colorado, United States | — |
| Clinical Research Consulting, LLC | Milford, Connecticut, United States | — |
| Innovative Research of West Florida, Inc. | Clearwater, Florida, United States | — |
| Velocity Clinical Research - New Smyrna Beach | Edgewater, Florida, United States | — |
| CenExel RCA | Hollywood, Florida, United States | — |
| Health Awareness INC | Jupiter, Florida, United States | — |
| Global Health Research Center | Miami Lakes, Florida, United States | — |
| Precision Clinical Research | Sunrise, Florida, United States | — |
| Global Health Research Center | Tampa, Florida, United States | — |
+ 35 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05501561